This is because obesity is a chronic and complex phenomenon, and its treatment is affected by multiple factors, not just medical ones
At six weeks, the average participant in a GLP-1 trial has lost a modest amount of weight, certainly not enough to account for a 20% reduction in major cardiovascular events through improved body composition alone
For example, there is a savings offer for Wegovy that may lower the price to $199 for one month if you qualify
The SELECT trial showed that semaglutide reduced major cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in people with obesity but without diabetes
Exenatide microspheres for monthly controlled-release aided by magnesium hydroxide
Consult Your Doctor and Registered Dietitian Above all, you should have some level of medical supervision while on any medication